Search
STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial human data on its oral PTH1R agonist for hypoparathyroidism in Q1
Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk. Coverage brought to you by
2 hours ago
Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic
Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an overview of programs targeting MRGPRX2, PTH1R, and a collaboration with Novo on obesity. Coverage brought to you by
Apr 14
.png){kind=logo}
